Avalo Therapeutics, Inc. (AVTX) stock
AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.13−0.24 (-3.26%)
Close on Nov 17, 2026Market cap $382.38MP/E –Yield –
Avalo Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Avalo Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $64.35M, up 57.3% year over year. For fiscal 2025 it was $50.08M, up 105.0% from the year before. Over ten years it grew 22.5% a year on average. The highest annual figure on record is $59.84M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.08M | +105.0% |
| FY2024 | Dec 31, 2024 | $24.44M | +77.3% |
| FY2023 | Dec 31, 2023 | $13.78M | -56.0% |
| FY2022 | Dec 31, 2022 | $31.31M | -47.7% |
| FY2021 | Dec 31, 2021 | $59.84M | +85.9% |
| FY2020 | Dec 31, 2020 | $32.19M | +173.7% |
| FY2019 | Dec 31, 2019 | $11.76M | +103.3% |
| FY2018 | Dec 31, 2018 | $5.79M | +32.3% |
| FY2017 | Dec 31, 2017 | $4.37M | -56.9% |
| FY2016 | Dec 31, 2016 | $10.15M | +54.1% |
| FY2015 | Dec 31, 2015 | $6.59M | -46.2% |
| FY2014 | Dec 31, 2014 | $12.24M | +37.3% |
| FY2013 | Dec 31, 2013 | $8.91M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $23.42M | +66.4% |
| Q1 FY2026 | Mar 31, 2026 | $14.05M | +54.0% |
| Q4 FY2025 | Dec 31, 2025 | $13.27M | +62.1% |
| Q3 FY2025 | Sep 30, 2025 | $13.62M | +42.8% |
| Q2 FY2025 | Jun 30, 2025 | $14.07M | +205.9% |
| Q1 FY2025 | Mar 31, 2025 | $9.12M | +331.1% |
| Q4 FY2024 | Dec 31, 2024 | $8.18M | +338.3% |
| Q3 FY2024 | Sep 30, 2024 | $9.54M | +663.7% |
| Q2 FY2024 | Jun 30, 2024 | $4.60M | -1.2% |
| Q1 FY2024 | Mar 31, 2024 | $2.12M | -64.8% |
| Q4 FY2023 | Dec 31, 2023 | $1.87M | -69.8% |
| Q3 FY2023 | Sep 30, 2023 | $1.25M | -82.3% |
| Q2 FY2023 | Jun 30, 2023 | $4.66M | -45.3% |
| Q1 FY2023 | Mar 31, 2023 | $6.01M | -37.3% |
| Q4 FY2022 | Dec 31, 2022 | $6.17M | -46.4% |
| Q3 FY2022 | Sep 30, 2022 | $7.04M | -33.3% |
| Q2 FY2022 | Jun 30, 2022 | $8.51M | -32.3% |
| Q1 FY2022 | Mar 31, 2022 | $9.58M | -62.0% |
| Q4 FY2021 | Dec 31, 2021 | $11.51M | -8.9% |
| Q3 FY2021 | Sep 30, 2021 | $10.55M | +18.9% |
| Q2 FY2021 | Jun 30, 2021 | $12.57M | +112.4% |
| Q1 FY2021 | Mar 31, 2021 | $25.21M | +428.6% |
| Q4 FY2020 | Dec 31, 2020 | $12.64M | +334.7% |
| Q3 FY2020 | Sep 30, 2020 | $8.87M | +408.9% |
| Q2 FY2020 | Jun 30, 2020 | $5.92M | +59.4% |
| Q1 FY2020 | Mar 31, 2020 | $4.77M | +40.2% |
| Q4 FY2019 | Dec 31, 2019 | $2.91M | +44.9% |
| Q3 FY2019 | Sep 30, 2019 | $1.74M | +66.4% |
| Q2 FY2019 | Jun 30, 2019 | $3.71M | +242.9% |
| Q1 FY2019 | Mar 31, 2019 | $3.40M | +106.2% |
| Q4 FY2018 | Dec 31, 2018 | $2.01M | +2.3% |
| Q3 FY2018 | Sep 30, 2018 | $1.05M | +8.6% |
| Q2 FY2018 | Jun 30, 2018 | $1.08M | +119.3% |
| Q1 FY2018 | Mar 31, 2018 | $1.65M | +73.1% |
| Q4 FY2017 | Dec 31, 2017 | $1.96M | +153.7% |
| Q3 FY2017 | Sep 30, 2017 | $964.57K | -78.9% |
| Q2 FY2017 | Jun 30, 2017 | $493.65K | – |
| Q1 FY2017 | Mar 31, 2017 | $953.07K | – |
| Q4 FY2016 | Dec 31, 2016 | $773.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $4.58M | – |
See a number that looks wrong?